Table 4 Iron-related parameters and concomitant IV iron and ESA use at baseline and during follow-up (Q1 to Q4) in the overall study cohort (N = 1096)

Serum ferritin, μg/L

456 ± 331

481 ± 329^**

502 ± 330^***

495 ± 320^*

488 ± 337^*

Serum TSAT, %

27.9 ± 12.1

29.4 ± 12.0^*

29.9 ± 12.1^*

29.3 ± 12.4

28.9 ± 11.6

Hemoglobin, g/L

113.2 ± 12.4

114.7 ± 13.1^**

113.9 ± 13.9

115.5 ± 12.6^**

114.9 ± 13.1

Patients receiving IV iron, n (%)

856 (78.6)

739 (76.3)

552 (74.8)^*

388 (72.4)^*

279 (73.8)

Mean IV iron dose, mg/week

54.4

51.4

48.5^*

47.1^*

50.0

Patients receiving ESA, n (%)

877 (80.5)

751 (77.6)

569 (77.2)

402 (77.1)^*

282 (74.6)^*

Mean ESA dose, units/week

6618

5945^***

5846^*

6126^*

5665^*